Jim Flatt is listed as an executive officer and director on 3 SEC Form D filings by 1 issuer between Apr 2025 and Dec 2025: DMC Biotechnologies, Inc. (Boulder, CO — biotechnology — 2025; $33.8M reported sold to 12 investors).
What this means One deal on file with the SEC, filed Dec 2025. A Form D is the notice a company files after it starts selling a private investment — it is a notice, not an approval.
Listed alongside Alastair Cooper (3 shared filings), Doug Cameron (3 shared filings), Josh Yelen (3 shared filings), Josko Bobanovic (3 shared filings), K'Lynne Johnson (3 shared filings) and 2 others.
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jim. Each name links to their own page.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AK, AL, AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, IL, KS, KY, LA, MA, MD, ME, MI, MO, MS, MT, NASAA, NC, ND, NH, NM, NV, OK, OR, PA, RI, SC, SD, TN, TX, VT, WA, WI, WV, WY) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 3 public filings for Jim Flatt and found 3 differences: Form D filed 60 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.